
    
      This Phase IIa exploratory 2-stage trial assessed the efficacy, safety and tolerability of
      CPC634 (CriPec® docetaxel) administered IV, Q3W to 25 subjects (13 in Stage 1 and 12 in Stage
      2) with ovarian cancer that is resistant to prior platinum-based therapy. Subjects will be
      treated continuously every 21 days at 60 mg/m2, which is the RP2D of CPC634 (CriPec®
      docetaxel) that was determined in the Phase I CT-CL01, until disease progression,
      unacceptable toxicity, or discontinuation for any other reason.
    
  